Related references
Note: Only part of the references are listed.Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Meagan B. Ryan et al.
CLINICAL CANCER RESEARCH (2020)
The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin et al.
CANCER DISCOVERY (2020)
Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers
F. Coussy et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
Ufuk Degirmenci et al.
CELLS (2020)
Targeting ERK-Hippo Interplay in Cancer Therapy
Karel Valis et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
RAS, wanted dead or alive: Advances in targeting RAS mutant cancers
Clint A. Stalnecker et al.
SCIENCE SIGNALING (2020)
RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors
Xi Yuan et al.
MOLECULAR ONCOLOGY (2020)
Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs
Michael J. Bond et al.
ACS CENTRAL SCIENCE (2020)
Exploring Targeted Degradation Strategy for Oncogenic KRASG12C
Mei Zeng et al.
CELL CHEMICAL BIOLOGY (2020)
EGF receptor and PKC kinase activate DNA damage-induced pro-survival and pro-apoptotic signaling via biphasic activation of ERK and MSK1 kinases
Angela M. Ohm et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
Kirsten L. Bryant et al.
NATURE MEDICINE (2019)
Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
Conan G. Kinsey et al.
NATURE MEDICINE (2019)
AMP-activated protein kinase: the current landscape for drug development
Gregory R. Steinberg et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival
Chih-Shia Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF
Amber Y. Gunderwala et al.
ACS CHEMICAL BIOLOGY (2019)
V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer
Yijun Gao et al.
CANCER DISCOVERY (2019)
RAS Mutations Are Not Created Equal
G. Aaron Hobbs et al.
CANCER DISCOVERY (2019)
The strange case of AMPK and cancer: Dr Jekyll or Mr Hyde?
Diana Vara-Ciruelos et al.
OPEN BIOLOGY (2019)
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Jiajun Yap et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2019)
AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells
Jimena Trillo-Tinoco et al.
CANCER RESEARCH (2019)
Cryo-EM structure of a dimeric B-Raf:14-3-3 complex reveals asymmetry in the active sites of B-Raf kinases
Yasushi Kondo et al.
SCIENCE (2019)
Architecture of autoinhibited and active BRAF-MEK1-14-3-3 complexes
Eunyoung Park et al.
NATURE (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling
Zhan Yao et al.
NATURE MEDICINE (2019)
Fibroblast growth factor receptors as treatment targets in clinical oncology
Masaru Katoh
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
The ERK and JNK pathways in the regulation of metabolic reprogramming
Salvatore Papa et al.
ONCOGENE (2019)
Inhibition of Adenosine Monophosphate-Activated Protein Kinase-3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Signaling Leads to Hypercholesterolemia and Promotes Hepatic Steatosis and Insulin Resistance
Kim Loh et al.
HEPATOLOGY COMMUNICATIONS (2019)
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Ferdinandos Skoulidis et al.
NATURE REVIEWS CANCER (2019)
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Ryan J. Sullivan et al.
CANCER DISCOVERY (2018)
Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers
Andrew J. Aguirre et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
Matthew R. Janes et al.
CELL (2018)
AMPK promotes survival of c-Myc-positive melanoma cells by suppressing oxidative stress
Alain Kfoury et al.
EMBO JOURNAL (2018)
The AMPK inhibitor overcomes the paradoxical effect of RAF inhibitors through blocking phospho-Ser-621 in the C terminus of CRAF
Jimin Yuan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function
Lixin Wan et al.
MOLECULAR CELL (2018)
AMP kinase promotes glioblastoma bioenergetics and tumour growth
Rishi Raj Chhipa et al.
NATURE CELL BIOLOGY (2018)
The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants
Jimin Yuan et al.
ONCOGENE (2018)
Autophagy Sustains Pancreatic Cancer Growth through Both Cell-Autonomous and nonautonomous Mechanisms
Annan Yang et al.
CANCER DISCOVERY (2018)
Targeting the MAPK Pathway in RAS Mutant Cancers
Sarah G. Hymowitz et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers
Jeffrey A. Knauf et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer
Di Wu et al.
NATURE (2018)
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1-and RAS-driven cancers
Robert J. Nichols et al.
NATURE CELL BIOLOGY (2018)
Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways
Benoit Tessoulin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Activating mutations in MEK1 enhance homodimerization and promote tumorigenesis
Jimin Yuan et al.
SCIENCE SIGNALING (2018)
Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
Sunilkumar Kakadia et al.
ONCOTARGETS AND THERAPY (2018)
Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells
Arun M. Unni et al.
ELIFE (2018)
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors
Stergios J. Moschos et al.
JCI INSIGHT (2018)
Metabolic stress regulates ERK activity by controlling KSR-RAF heterodimerization
Amandine Verlande et al.
EMBO REPORTS (2018)
From tumour heterogeneity to advances in precision treatment of colorectal cancer
Cornelis J. A. Punt et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Genomics of Hairy Cell Leukemia
Enrico Tiacci et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2017)
Fructose-1,6-bisphosphate and aldolase mediate glucose sensing by AMPK
Chen-Song Zhang et al.
NATURE (2017)
RAF1/BRAF dimerization integrates the signal from RAS to ERK and ROKα
Andrea Varga et al.
SCIENCE SIGNALING (2017)
A Role for Mitochondrial Translation in Promotion of Viability in K-Ras Mutant Cells
Timothy D. Martin et al.
CELL REPORTS (2017)
A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution
Grace R. Anderson et al.
CELL REPORTS (2017)
RAF1/BRAF dimerization integrates the signal from RAS to ERK and ROKα
Andrea Varga et al.
SCIENCE SIGNALING (2017)
Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant or ALK-Positive Non-Small-Cell Lung Cancer With Brain Metastases
Pablo Martinez et al.
JAMA ONCOLOGY (2017)
Amino acid homeostasis and signalling in mammalian cells and organisms
Stefan Broer et al.
BIOCHEMICAL JOURNAL (2017)
Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras
Tim Wang et al.
CELL (2017)
Recent advances in RASopathies
Yoko Aoki et al.
JOURNAL OF HUMAN GENETICS (2016)
AMPK regulates autophagy by phosphorylating BECN1 at threonine 388
Deyi Zhang et al.
AUTOPHAGY (2016)
Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells
Zhen Li et al.
CANCER LETTERS (2016)
A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
Sai Krishna Athuluri-Divakar et al.
CELL (2016)
B-Raf activation loop phosphorylation revisited
Martin Koehler et al.
CELL CYCLE (2016)
AMPK Is Essential to Balance Glycolysis and Mitochondrial Metabolism to Control T-ALL Cell Stress and Survival
Rigel J. Kishton et al.
CELL METABOLISM (2016)
The ERK cascade inhibitors: Towards overcoming resistance
Galia Maik-Rachline et al.
DRUG RESISTANCE UPDATES (2016)
AMP-activated protein kinase: a cellular energy sensor that comes in 12 flavours
Fiona A. Ross et al.
FEBS JOURNAL (2016)
Recent insights into the function of autophagy in cancer
Ravi Amaravadi et al.
GENES & DEVELOPMENT (2016)
Autophagy provides metabolic substrates to maintain energy charge and nucleotide pools in Ras-driven lung cancer cells
Jessie Yanxiang Guo et al.
GENES & DEVELOPMENT (2016)
RAS isoforms and mutations in cancer at a glance
G. Aaron Hobbs et al.
JOURNAL OF CELL SCIENCE (2016)
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Evolving molecularly targeted therapies for advanced-stage thyroid cancers
Keith C. Bible et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
AMPK promotes tolerance to Ras pathway inhibition by activating autophagy
S. Sanduja et al.
ONCOGENE (2016)
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Piro Lito et al.
SCIENCE (2016)
AMP-activated protein kinase mediates mitochondrial fission in response to energy stress
Erin Quan Toyama et al.
SCIENCE (2016)
AMPK: An Energy-Sensing Pathway with Multiple Inputs and Outputs
D. Grahame Hardie et al.
TRENDS IN CELL BIOLOGY (2016)
Evolving Lessons on the Complex Role of AMPK in Normal Physiology and Cancer
Biplab Dasgupta et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
A systems study reveals concurrent activation of AMPK and mTOR by amino acids
Piero Dalle Pezze et al.
NATURE COMMUNICATIONS (2016)
Progress on Covalent Inhibition of KRASG12C
Kenneth D. Westover et al.
CANCER DISCOVERY (2016)
BRAFV600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells
Toshinori Sueda et al.
SCIENTIFIC REPORTS (2016)
Amino acids and autophagy: their crosstalk, interplay and interlock
Chien-An A. Hu et al.
AMINO ACIDS (2015)
Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes
Ana Herrero et al.
CANCER CELL (2015)
Inhibition of RAF lsoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
Sheng-Bin Peng et al.
CANCER CELL (2015)
Degradation of AMPK by a Cancer-Specific Ubiquitin Ligase
Carlos T. Pineda et al.
CELL (2015)
Global Phosphoproteomic Analysis of Human Skeletal Muscle Reveals a Network of Exercise-Regulated Kinases and AMPK Substrates
Nolan J. Hoffman et al.
CELL METABOLISM (2015)
AMPK Protects Leukemia-Initiating Cells in Myeloid Leukemias from Metabolic Stress in the Bone Marrow
Yusuke Saito et al.
CELL STEM CELL (2015)
Motif affinity and mass spectrometry proteomic approach for the discovery of cellular AMPK targets: Identification of mitochondrial fission factor as a new AMPK substrate
Serge Ducommun et al.
CELLULAR SIGNALLING (2015)
RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
Julian Downward
CLINICAL CANCER RESEARCH (2015)
MicroRNA-455 regulates brown adipogenesis via a novel HIF1an-AMPK-PGC1 signaling network
Hongbin Zhang et al.
EMBO REPORTS (2015)
BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers
Zhiyu Tang et al.
MOLECULAR CANCER THERAPEUTICS (2015)
RAF inhibitors that evade paradoxical MAPK pathway activation
Chao Zhang et al.
NATURE (2015)
Regulation of RAF protein kinases in ERK signalling
Hugo Lavoie et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Atg7 Overcomes Senescence and Promotes Growth of BrafV600E-Driven Melanoma
Xiaoqi Xie et al.
CANCER DISCOVERY (2015)
Melanoma
Dirk Schadendorf et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
A Novel MEK-ERK-AMPK Signaling Axis Controls Chemokine Receptor CCR7-dependent Survival in Human Mature Dendritic Cells
Pilar Lopez-Cotarelo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Kinase Regulation by Hydrophobic Spine Assembly in Cancer
Jiancheng Hu et al.
MOLECULAR AND CELLULAR BIOLOGY (2015)
Structure of the BRAF-MEK Complex Reveals a Kinase Activity Independent Role for BRAF in MAPK Signaling
Jacob R. Haling et al.
CANCER CELL (2014)
ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
Eva M. Goetz et al.
CANCER RESEARCH (2014)
AMPK Reverses the Mesenchymal Phenotype of Cancer Cells by Targeting the Akt-MDM2-Foxo3a Signaling Axis
Chih-Chien Chou et al.
CANCER RESEARCH (2014)
AMPK-Sensing Energy while Talking to Other Signaling Pathways
D. Grahame Hardie
CELL METABOLISM (2014)
Metabolic-Stress-Induced Rearrangement of the 14-3-3ζ Interactome Promotes Autophagy via a ULK1-and AMPK-Regulated 14-3-3ζ Interaction with Phosphorylated Atg9
Vajira K. Weerasekara et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
Kinases and Pseudokinases: Lessons from RAF
Andrey S. Shaw et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Drugging the undruggable RAS: Mission Possible?
Adrienne D. Cox et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Evidence for the Role of AMPK in Regulating PGC-1 Alpha Expression and Mitochondrial Proteins in Mouse Epididymal Adipose Tissue
Zhongxiao Wan et al.
OBESITY (2014)
Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway
Matthias Drosten et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Eliezer M. Van Allen et al.
CANCER DISCOVERY (2014)
Autophagy Is Critical for Pancreatic Tumor Growth and Progression in Tumors with p53 Alterations
Annan Yang et al.
CANCER DISCOVERY (2014)
Oncogene Mimicry as a Mechanism of Primary Resistance to BRAF Inhibitors
Martin L. Sos et al.
CELL REPORTS (2014)
Energy Stress Regulates Hippo-YAP Signaling Involving AMPK-Mediated Regulation of Angiomotin-like 1 Protein
Michael DeRan et al.
CELL REPORTS (2014)
Phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) is an AMPK target participating in contraction-stimulated glucose uptake in skeletal muscle
Yang Liu et al.
BIOCHEMICAL JOURNAL (2013)
Pseudokinases from a structural perspective
Susan S. Taylor et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2013)
Coordinated time-dependent modulation of AMPK/Akt/mTOR signaling and autophagy controls osteogenic differentiation of human mesenchymal stem cells
Aleksandar Pantovic et al.
BONE (2013)
LKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug Phenformin
David B. Shackelford et al.
CANCER CELL (2013)
Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
Ryan B. Corcoran et al.
CANCER CELL (2013)
Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity
Nobuya Ishii et al.
CANCER RESEARCH (2013)
Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers
Jiancheng Hu et al.
CELL (2013)
AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo
Brandon Faubert et al.
CELL METABOLISM (2013)
Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis
Jessie Yanxiang Guo et al.
GENES & DEVELOPMENT (2013)
Chemoproteomic Analysis of Intertissue and Interspecies Isoform Diversity of AMP-activated Protein Kinase (AMPK)
Jiang Wu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
MEK and the inhibitors: from bench to bedside
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
B-Raf and the inhibitors: from bench to bedside
Tiangui Huang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Dysregulating IRES-Dependent Translation Contributes to Overexpression of Oncogenic Aurora A Kinase
Tara Dobson et al.
MOLECULAR CANCER RESEARCH (2013)
Phosphorylation of BRAF by AMPK Impairs BRAF-KSR1 Association and Cell Proliferation
Che-Hung Shen et al.
MOLECULAR CELL (2013)
AMPK-Dependent Degradation of TXNIP upon Energy Stress Leads to Enhanced Glucose Uptake via GLUT1
Ning Wu et al.
MOLECULAR CELL (2013)
p53 status determines the role of autophagy in pancreatic tumour development
Mathias T. Rosenfeldt et al.
NATURE (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma
Ping Yuan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Autophagy Sustains Mitochondrial Glutamine Metabolism and Growth of BrafV600E-Driven Lung Tumors
Anne M. Strohecker et al.
CANCER DISCOVERY (2013)
PAF-Mediated MAPK Signaling Hyperactivation via LAMTOR3 Induces Pancreatic Tumorigenesis
Sohee Jun et al.
CELL REPORTS (2013)
AMP-activated protein kinase: new regulation, new roles?
David Carling et al.
BIOCHEMICAL JOURNAL (2012)
AMP-activated protein kinase phosphorylates and inactivates liver glycogen synthase
Laurent Bultot et al.
BIOCHEMICAL JOURNAL (2012)
A Comprehensive Survey of Ras Mutations in Cancer
Ian A. Prior et al.
CANCER RESEARCH (2012)
First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors
Maria Martinez-Garcia et al.
CLINICAL CANCER RESEARCH (2012)
Kinase Suppressor of Ras 2 (KSR2) Regulates Tumor Cell Transformation via AMPK
Mario R. Fernandez et al.
MOLECULAR AND CELLULAR BIOLOGY (2012)
The AMPK β2 Subunit Is Required for Energy Homeostasis during Metabolic Stress
Biplab Dasgupta et al.
MOLECULAR AND CELLULAR BIOLOGY (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress
Sang-Min Jeon et al.
NATURE (2012)
Deregulated MYC expression induces dependence upon AMPK-related kinase 5
Lidan Liu et al.
NATURE (2012)
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Timothy R. Wilson et al.
NATURE (2012)
ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect
Weiwei Yang et al.
NATURE CELL BIOLOGY (2012)
AMPK activators inhibit the proliferation of human melanomas bearing the activated MAPK pathway
Carlotta Petti et al.
MELANOMA RESEARCH (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
AMPK functions as an adenylate charge-regulated protein kinase
Jonathan S. Oakhill et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2012)
Amino acids and mTORC1: from lysosomes to disease
Alejo Efeyan et al.
TRENDS IN MOLECULAR MEDICINE (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker
Flavio Solca et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Pancreatic cancers require autophagy for tumor growth
Shenghong Yang et al.
GENES & DEVELOPMENT (2011)
Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis
Jessie Yanxiang Guo et al.
GENES & DEVELOPMENT (2011)
Single Substitution within the RKTR Motif Impairs Kinase Activity but Promotes Dimerization of RAF Kinase
Angela Baljuls et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
The AMPK signalling pathway coordinates cell growth, autophagy and metabolism
Maria M. Mihaylova et al.
NATURE CELL BIOLOGY (2011)
AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
Joungmok Kim et al.
NATURE CELL BIOLOGY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF
Jiancheng Hu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy
Daniel F. Egan et al.
SCIENCE (2011)
The Raf Inhibitor Paradox: Unexpected Consequences of Targeted Drugs
Adrienne D. Cox et al.
CANCER CELL (2010)
Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells
Zhenfeng Zhang et al.
CARCINOGENESIS (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
Downregulation of AMPK Accompanies Leucine- and Glucose-Induced Increases in Protein Synthesis and Insulin Resistance in Rat Skeletal Muscle
Asish K. Saha et al.
DIABETES (2010)
ERK and cell death: Mechanisms of ERK-induced cell death - apoptosis, autophagy and senescence
Sebastien Cagnol et al.
FEBS JOURNAL (2010)
From basic research to clinical development of MEK1/2 inhibitors for cancer therapy
Christophe Fremin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2010)
Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling
Daniel A. Ritt et al.
MOLECULAR AND CELLULAR BIOLOGY (2010)
Glucose Addiction of TSC Null Cells Is Caused by Failed mTORC1-Dependent Balancing of Metabolic Demand with Supply
Andrew Y. Choo et al.
MOLECULAR CELL (2010)
Network organization of the human autophagy system
Christian Behrends et al.
NATURE (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells
Claudia Scholl et al.
CELL (2009)
KSR2 Is an Essential Regulator of AMP Kinase, Energy Expenditure, and Insulin Sensitivity
Diane L. Costanzo-Garvey et al.
CELL METABOLISM (2009)
The C-terminus of Raf-1 acts as a 14-3-3-dependent activation switch
Amardeep S. Dhillon et al.
CELLULAR SIGNALLING (2009)
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
Stephen Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Oncogenic B-RAF Negatively Regulates the Tumor Suppressor LKB1 to Promote Melanoma Cell Proliferation
Bin Zheng et al.
MOLECULAR CELL (2009)
A dimerization-dependent mechanism drives RAF catalytic activation
Thanashan Rajakulendran et al.
NATURE (2009)
MEK1 mutations confer resistance to MEK and B-RAF inhibition
Caroline M. Emery et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Negative-feedback regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within the DUSP6/MKP-3 gene promoter
Maria Ekerot et al.
BIOCHEMICAL JOURNAL (2008)
Hypothalamic CaMKK2 contributes to the regulation of energy balance
Kristin A. Anderson et al.
CELL METABOLISM (2008)
Muscarinic receptor activation of AMP-activated protein kinase inhibits orexigenic neuropeptide mRNA expression
Claire Thornton et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Discovery of TBC1D1 as an insulin-, AICAR-, and contraction-stimulated signaling nexus in mouse skeletal muscle
Eric B. Taylor et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
AMPK phosphorylation of raptor mediates a metabolic checkpoint
Dana M. Gwinn et al.
MOLECULAR CELL (2008)
Targeting EGFR in colorectal cancer
Wells A. Messersmith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
D. Li et al.
ONCOGENE (2008)
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
James Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Localization of AMP kinase is regulated by stress, cell density, and signaling through the MEK → ERK1/2 pathway
Mohamed Kodiha et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2007)
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
Javier A. Menendez et al.
NATURE REVIEWS CANCER (2007)
B- and C-RAF display essential differences in their binding to Ras - The isotype-specific N terminus of B-RAF facilitates ras binding
Andreas Fischer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The role of AMPK and mTOR in nutrient sensing in pancreatic β-cells
Catherine E. Gleason et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling
Nicolas Dumaz et al.
CANCER RESEARCH (2006)
Thrombin activates AMP-activated protein kinase in endothelial cells via a pathway involving Ca2+/calmodulin-dependent protein kinase kinase β
Nadine Stahmann et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
AMPK-mediated AS160 phosphorylation in skeletal muscle is dependent on AMPK catalytic and regulatory subunits
Jonas T. Treebak et al.
DIABETES (2006)
A balance between Raf-1 and Fas expression sets the pace of erythroid differentiation
Cristina Rubiolo et al.
BLOOD (2006)
Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma
DJ Panka et al.
CLINICAL CANCER RESEARCH (2006)
Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy
Filippo Montemurro et al.
ONCOLOGIST (2006)
Regulation and role of Raf-1/B-Raf heterodimerization
LK Rushworth et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases
RL Hurley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Ca2+/calmodulin-dependent protein kinase kinase-β acts upstream of AMP-activated protein kinase in mammalian cells
A Woods et al.
CELL METABOLISM (2005)
Calmodulin-dependent protein kinase kinase-β is an alternative upstream kinase for AMP-activated protein kinase
SA Hawley et al.
CELL METABOLISM (2005)
Adenosine 5′-monophosphate-activated protein kinase and p38 mitogen-activated protein kinase participate in the stimulation of glucose uptake by dinitrophenol in adult cardiomyocytes
A Pelletier et al.
ENDOCRINOLOGY (2005)
Effects of α-AMPK knockout on exercise-induced gene activation in mouse skeletal muscle
SB Jorgensen et al.
FASEB JOURNAL (2005)
Raf-1 regulates Rho signaling and cell migration
K Ehrenreiter et al.
JOURNAL OF CELL BIOLOGY (2005)
Regulation of raf-1 by direct feedback phosphorylation
MK Dougherty et al.
MOLECULAR CELL (2005)
A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells
E Yeh et al.
NATURE CELL BIOLOGY (2004)
AMP-activated protein kinase plays a role in the control of food intake
U Andersson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression
D Tripathy et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress
RJ Shaw et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte
AYM Chan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition
JF Ohren et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2004)
The LKB1 tumor suppressor negatively regulates mTOR signaling
RJ Shaw et al.
CANCER CELL (2004)
Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf
T Brummer et al.
ONCOGENE (2003)
LKB1 is the upstream kinase in the AMP-activated protein kinase cascade
A Woods et al.
CURRENT BIOLOGY (2003)
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its comolex with the microbial alkaloid K-252a
N Schiering et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300
NL Sang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Targeting ras signalling pathways in cancer therapy
J Downward
NATURE REVIEWS CANCER (2003)
Raf-1 antagonizes erythroid differentiation by restraining caspase activation
A Kolbus et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Role of AMP-activated protein kinase in mechanism of metformin action
GC Zhou et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia
AS Marsin et al.
CURRENT BIOLOGY (2000)
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability
R Sears et al.
GENES & DEVELOPMENT (2000)
Stimulation of AMP-activated protein kinase (AMPK) is associated with enhancement of Glut1-mediated glucose transport
W Abbud et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2000)
Fibroblast growth factor 2 internal ribosome entry site (IRES) activity ex vivo and in transgenic mice reveals a stringent tissue-specific regulation
L Créancier et al.
JOURNAL OF CELL BIOLOGY (2000)
Raf induces NF-κB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation
B Baumann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Overlapping and specific functions of Braf and Craf-1 proto-oncogenes during mouse embryogenesis
L Wojnowski et al.
MECHANISMS OF DEVELOPMENT (2000)
Share Paper
